Targeting a

Fuller Life

Rain Oncology develops innovative, targeted therapies to help patients with cancer get their life back.

We focus on cancers where we can genetically identify patients most likely to benefit from treatment.

milademetan clinical program

View Our Pipeline
Milademetan is an oral agent that targets the MDM2*-p53 interaction, a key mediator of many malignancies. Milademetan is currently in clinical development for patients with MDM2-dependent, TP53 wildtype cancers.

Resources & Publications

Rain in the News

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
November 9, 2023 4:01 PM
NEWARK, Calif., November 9, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations.
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
October 16, 2023 8:00 AM
NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain’s programs.
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 4:05 PM
NEWARK, Calif., August 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. “Rain has been aggressively pursuing a multitude of opportunities as we seek to leverage our clinical execution capabilities and strong cash position to add value to our shareholders”, said Avanish Vellanki, co-founder and chief executive officer of Rain. “Our efforts are focused on licensing or acquiring differentiated clinical-stage programs, as well as avenues to partner with companies utilizing proprietary technology that may help develop drug candidates entering the clinic. We are very excited about the progress we’ve made and recognize it’s important to act expeditiously. We will provide an update publicly on these endeavors at the appropriate time.”